Compare
CytoDyn Inc. vs Actuate Therapeutics, Inc. vs Chemomab Therapeutics Ltd. vs Biovie Inc.
| Latest fiscal year | CytoDyn Inc. CYDY | Actuate Therapeutics, Inc. ACTU | Chemomab Therapeutics Ltd. CMMB | Biovie Inc. BIVI |
|---|---|---|---|---|
| Year ended | 2026-05-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$42.70M | -$22.23M | -$8.99M | -$22.07M |
| EPS (Diluted) | -$0.03 | -$1.06 | $0.018 | -$3.05 |
| Operating cash flow | -$17.25M | -$19.21M | -$11.13M | -$19.02M |
| Free cash flow | n/a | n/a | -$11.13M | n/a |
| Cash & equivalents | $11.85M | $13.16M | $7.56M | $8.98M |
| Total assets | $13.97M | $14.04M | $13.81M | $14.25M |
| Total liabilities | $123.69M | $6.11M | $1.48M | $3.98M |
| Shareholders' equity | -$109.72M | $7.92M | $12.33M | $10.27M |
| Return on year-end equity | n/a | -280.5% | -72.9% | -214.9% |
| Shares outstanding | 1.37B | 23.25M | n/a | 7.54M |
Revenue, most recent five fiscal years
| Fiscal year | CytoDyn Inc. | Actuate Therapeutics, Inc. | Chemomab Therapeutics Ltd. | Biovie Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-05-31 | n/a | n/a | n/a |
| 1 year earlier | $266.0K Ended 2022-05-31 | n/a | n/a | n/a |
| 2 years earlier | $0 Ended 2021-05-31 | n/a | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |